Centre for Molecular Inflammation and Vascular Research, Department of Medicine and Therapeutics, Mater Misericordiae Hospital, The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 7, Ireland
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Lipoxins (LX) are
eicosanoids generated via transcellular biosynthetic routes during
inflammation, hypersensitivity reaction, and after angioplasty. LXs are
modulators of leukocyte trafficking and vascular tone. Their influence
on the coagulation cascade has not been determined. In this study, we
evaluated the influence of LXs on the expression of tissue factor (TF),
a key regulator of coagulation. TF activity was measured in lysates of
monocytes, human umbilical vein endothelial cells, and ECV304 cells
using a one-stage clotting assay. LXA4 stimulated TF
activity in each cell type. The influence of LXA4 on TF
activity by ECV304 cells was studied further to explore the mechanism
of induction of TF expression. LXA4-induced TF activity was
dose dependent, cycloheximide sensitive, and associated with increased
TF mRNA levels. Induction of TF activity was specific for
LXA4 and was not observed with LXB4, the other
major lipoxin generated by mammalian cells. Furthermore, ECV304 cell TF
expression was not influenced by
15(R/S)-methyl-LXA4 or
16-phenoxy-LXA4, synthetic analogs of LXA4 that
activate the myeloid LXA4 receptor, and was not modulated
by SKF-104353, which blocks LXA4 bioactivities transduced
through the putative shared LXA4/LTD4 receptor.
LXA4-stimulated TF expression was blunted by pertussis
toxin and by GF-109203X, an inhibitor of protein kinase C, and was not
associated with degradation of IB
. Our results establish that
LXA4 induces TF activity via cell signaling pathways with
different structural and receptor requirements from those described for
inhibition of leukocyte-endothelial cell interactions. They suggest a
role for LXA4 as a modulator of TF-related vascular events
during inflammation and thrombosis.
monocytes; endothelial cells; receptors; gene expression
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LIPOXINS (LX) are eicosanoids generated via biosynthetic pathways that involve the dual lipoxygenation of arachidonic acid by either 5- and 15-lipoxygenases or 5- and 12-lipoxygenases (lipoxygenase interaction products) (4). They are generated in vivo during host defense, inflammation, and hypersensitivity reactions and after percutaneous transluminal coronary angioplasty (PTCA) (4, 6). LXA4 and LXB4, the major LXs generated in mammalian systems, are inhibitors of neutrophil chemotaxis, adhesion, and transmigration induced by leukotrienes (LTs) and some other mediators and are putative endogenous "breaking signals" for leukocyte recruitment that promote resolution of inflammation (4). In addition to their actions with hematogenous cells, LXA4 and LXB4 have been reported to stimulate endothelial-dependent vasodilatation, inhibit endothelial cell P-selectin expression and hyperadhesiveness induced by LTs (28), and inhibit cytokine triggered interleukin (IL)-8 release by colonic epithelial cells (19). Thus LX formed during vascular events have the potential to influence the function of hematogenous cells and resident cells of the vessel wall.
The influence of LX on the coagulation cascade has not been determined. As an initial assessment of this issue, we evaluated the influence of LX on tissue factor (TF) expression. TF is a transmembrane glycoprotein that is a key regulator of blood coagulation (17). When expressed on the surface of cells such as endothelium, TF binds with high affinity to factor VII, leading to rapid formation of factor VIIa. The resulting TF-factor VIIa complex activates factors IX and X, leading to thrombin generation and subsequent fibrin deposition (17). Hematogenous cells and endothelial cells do not express TF constitutively; however, TF is transiently induced in endothelial cells after physical or inflammatory perturbation of the vessel wall. During inflammation and atherosclerosis, TF is induced in monocyte and endothelial cells by a variety of agonists, including bacterial lipopolysaccharide (LPS), inflammatory cytokines, and oxidized low-density lipoproteins (2, 12, 13, 16). TF is also rapidly induced in the vessel wall as a consequence of acute arterial injury during PTCA (35). TF is constitutively expressed by many vascular wall cells external to the endothelial monolayer, and its expression is further induced in these cells by inflammatory stimuli.
Here we explored the influence of LX on TF expression by monocytes, human umbilical vein endothelial cells (HUVEC), and ECV304 cells, cell-types chosen as models of hematogenous and vascular wall systems that 1) do not express TF under basal conditions but can be induced to express TF by inflammatory mechanisms (monocytes, HUVEC) and 2) nonendothelial parenchymal cells that constitutively express TF (ECV304 cells). We present evidence that LXA4 stimulates TF activity via a receptor-mediated signaling pathway that induces TF gene expression.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials.
Synthetic
5S,6R,15S-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic
acid (LXA4),
5S,14R,15S-trihydroxy-6,10,12-trans-8-cis-eicosatetraenoic acid (LXB4), and
5Z,8Z, 11Z,13E,15(S)-15-hydroxyeicosatetraenoic acid
(15-(S)-HETE) were purchased from Cascade Biochem
(Berkshire, UK). Synthetic analogs
15(R/S)-methyl-LXA4
(5S,6R,15R/S-trihydroxy-15-methyl-7,9,13-trans-11-cis-eicosatetraenoic acid methyl ester) and 16-phenoxy-LXA4
(15S-16-phenoxy-17,18,19,20-tetranor-LXA4 methyl
ester) were prepared by total synthesis by Dr. N. A. Petasis and
Dr. V. V. Fokin as previously described (34). Human
recombinant tumor necrosis factor (TNF)- was obtained from R & D
systems (Minneapolis, MN); arachidonic acid, bacterial endotoxin (LPS, Escherichia coli serotype 0111:B4), pertussis toxin,
NG-monomethyl-L-arginine
(L-NMMA), and cycloheximide from Sigma (St. Louis, MO); and
GF-109203X and genistein from Calbiochem (San Diego, CA). SFK-104353
was a kind gift from SmithKline Beecham Pharmaceuticals. Rabbit
anti-human TF antibody and recombinant human TF were purchased from
American Diagnostica (Greenwich, CT). The anti-I
B
rabbit
anti-human polyclonal antibody and the purified protein I
B
were
from Santa Cruz Biotechnology (Santa Cruz, CA). A 641-bp fragment of
the human TF cDNA was generated by EcoR I digestion of the
pcTF314 containing TF cDNA plasmid (26).
Cell culture and treatments. Human monocytes were obtained from whole blood collected from healthy donors and anticoagulated with 3.8% sodium citrate. Mononuclear cells were separated with Ficoll-Paque solution (Pharmacia, Biotec, Uppsala, Sweden) at 450 g for 20 min. To minimize platelet contamination, the cells were washed with PBS (Bio-Whittaker) containing 5 mM EDTA and suspended in RPMI 1640 supplemented with 10% autologous serum, 2 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin (GIBCO, Grand Island, NY). Cells were placed in 12-well plastic tissue culture plates (Costar, Cambridge, MA) at 2 × 106 cells per well and kept at 37°C in a 5% CO2 humidified atmosphere for 2 h. Supernatants containing nonadherent cells were removed, and adherent monocytes were washed twice with prewarmed medium.
Primary cultures of HUVECs were obtained from collagenase-digested umbilical veins or from Clonetics (San Diego, CA). The cells used for this study were between the second and the fourth passage and propagated in medium 199 (Sigma) supplemented with 20% fetal calf serum (GIBCO), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin in the presence of 50 µg/ml heparin and 50 µg/ml of endothelial cell growth factor (Sigma). ECV304 cells, a spontaneously immortalized cell line (36), were obtained from the European Collection of Animal Cell Cultures (Salisbury, UK). ECV304 cells express TF under basal condition and display increased TF expression in response to cytokine stimulation (23), providing a convenient model for assessment of both constitutive and inducible TF expression. ECV304 cells were maintained in medium 199 supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. For each experiment, cells were cultured in 12-well plastic tissue culture plates for assay of TF activity and in 100-mm dishes (Costar, Cambridge, MA) for RNA isolation. Cells were incubated in serum free medium with the appropriate stimuli as described. When inhibitors (pertussis toxin, L-NMMA, GF-109203X, genistein, cycloheximide) were used, they were incubated with ECV304 cells before the addition of LXA4, as described. At the end of the indicated incubation times, the medium was discarded and the cells were washed twice with serum-free medium 199 and the plates stored atTF activity determination.
For determination of TF activity, the cells were lysed with 16 mM
octyl--D-glycopyranoside at 37°C for 15 min. TF
activity in cell lysates was determined by a one-stage clotting assay
(39). The assay mixture contained 0.1 ml cell lysates; 0.1 ml citrated, pooled, normal plasma; and 0.1 ml of 25 mM
CaCl2. Clotting times were determined at 37°C. The values
were converted to arbitrary units of procoagulant activity by
comparison with a standard curve of clotting times obtained by serial
dilutions of rabbit brain thromboplastin (Sigma). This preparation was
assigned a value of 2,000 U for a clotting time of 40 s. In some
experiments, results were also expressed in nanograms of TF by
comparison with a standard curve obtained by using a recombinant human
TF lipidated lipoprotein standard. Protein concentration was determined
on cell lysates using the method of Bradford (3).
Analysis of IB
levels by Western blot.
ECV304 cells in six-well plates were incubated with LXA4 or
TNF-
for various times. Treatment was terminated by washing twice with ice-cold PBS. Cells were then scraped in 200 µl of ice-cold lysis buffer (40 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 20 µM
EDTA, 0.1% Triton-X 100) including a cocktail of protease inhibitors (2 µM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 20 mM
-glycerophosphate, 1 µM sodium orthophosphate, and 0.5 mM
dithiothreitol). Samples were then centrifuged at 14,000 g
for 20 min at 4°C, and the supernatant was removed as cell lysates.
Equal amounts of protein of denatured cell extracts and a purified
protein I
B
standard were resolved by electrophoresis on a 10%
SDS polyacrylamide gel and transferred to Immobilon-P polyvinyldiene
difluoride membranes (Millipore). The membrane was probed with the
anti-I
B
rabbit anti-human polyclonal antibody at a dilution of
1:2,500. To detect antibody reaction, the blots were incubated with an
alkaline phosphate conjugated anti-rabbit secondary antibody.
Immunoreactive proteins were detected using an alkaline phosphatase
liquid substrate system 5-bromo-4-chloro-3-indolyl phosphate/nitroblue
tetrazolium (Sigma).
RNA isolation and Northern blot analysis.
Total cellular RNA was isolated using TRIZOL reagent (Life
Technologies, Paisley, Scotland), a modification of the guanidinium isothiocyanate method (8). Total RNA (10 µg) was
electrophoresed in denaturing 1% agarose-formaldehyde gels
(31) and transferred overnight to nylon membranes (Hybond,
Amersham, Arlington Heights, IL) by capillary transfer in 20× sodium
chloride-sodium citrate. RNA was fixed to the membrane by baking at
80°C for 2 h. The membranes were prehybridized for 1 h at
68°C using Quikhyb hybridization solution (Stratagene, La Jolla, CA).
TF cDNA probe was labeled with [32P]dCTP (3,000 Ci/mmol, DuPont-NEN) by random priming (Boehringer Mannheim). This was
added to the Quikhyb solution, and the hybridization was carried out at
68°C for 2 h. Membranes were washed twice in 2× SSC, 0.1% SDS
for 30 min at room temperature, followed by one wash in 0.1× SSC,
0.1% SDS at 65°C. The membranes were then exposed to X-Omat Kodak
film (Eastman Kodak, Rochester, NY) with intensifying screens at
70°C. Equal loading of RNA was assessed relative to glucose-6-phosphate dehydrogenase mRNA levels.
Statistical analysis. Values are expressed as means ± SE. Statistical significance was assessed by paired Student's t-test.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Influence of LXA4 on TF activity.
The influence of LXA4 (109 M, 4 h)
on TF activity in monocytes, HUVECs, and ECV304 cells was
assessed and compared with TNF-
(10 ng/ml, 4 h) and LPS (10 µg/ml, 4 h), two well-defined inducers of TF activity. HUVECs
and monocytes do not express appreciable amounts of TF under basal
conditions. Exposure of adherent monocytes and HUVECs to
LXA4 (10
9 M, 4 h) increased TF activity
by almost two- and threefold over control, respectively.
LXA4-induced TF activity in HUVECs was similar in magnitude
to that observed with TNF-
treatment or with monocytes exposed to
LPS (Fig. 1).
|
|
LXA4-induced TF activity: structure-function
relationship.
Arachidonic acid did not induce ECV304 cell TF expression (Fig.
3), an important observation given that
LXA4 causes arachidonic acid release by leukocytes and
endothelial cells and that arachidonic acid can induce TF expression in
monocytes (7).
|
|
Receptor mechanisms involved in LXA4-triggered TF
activity.
The results of our structure-function studies described above, namely
stimulation of TF activity by nanomolar concentrations of
LXA4, but not LXB4, and 15(S)-HETE
suggest that ECV304 cells express specific high-affinity
LXA4 receptors. To explore this possibility further,
LXA4-stimulated TF activity was assessed after prior
exposure of ECV304 cells to pertussis toxin (100 ng/ml, 37°C, 18 h). Pertussis toxin completely inhibited LXA4-induced TF
activity (Fig. 4), suggesting involvement
of an LXA4 receptor coupled to Gi proteins.
|
Cell signaling pathways involved in LXA4-triggered TF
activity.
To explore the role of the protein kinase C (PKC) in the regulation of
TF activity by LXA4, we evaluated LXA4
bioactivity in the presence of GF-109203X, a pharmacological inhibitor
of PKC. Whereas GF-109203X (10 µM, 15 min) did not affect basal TF activity, prior exposure of ECV304 cells to this PKC inhibitor markedly
inhibited the LXA4-triggered response (Fig.
5). LXA4-stimulated TF
activity was also assessed in the presence of genistein, an inhibitor
of tyrosine kinase activity. In contrast to inhibiting PKC
activity, genistein (100 µM, 15 min) inhibited neither basal TF
activity nor LXA4-stimulated TF activity (Fig. 5).
|
Effect of LXA4 on IB
levels.
In the present study, exposure of ECV304 cells to LXA4
(10
7-10
9 M, 15 min-2 h) was not
associated with degradation of I
B
, as assessed by Western
blotting, in contrast to TNF-
(10 ng/ml), a well-defined stimulus
for activation of the NF-
B pathway (Fig. 6). Interestingly,
LXA4-induced TF activity was inhibited by
N
-tosylphenylalanyl chloromethyl ketone
(TPCK) and
N
-tosyl-L-lysine chloromethyl
ketone (TLCK), inhibitors of chymotrypsin-like serine proteases
that prevent nuclear factor (NF)-
B activation (24), suggesting other intracellular actions of these
pharmacological inhibitors (Table 2).
|
|
Effect of LXA4 on TF mRNA levels.
Induction of endothelial TF expression by LPS and cytokines is mediated
through activation of gene transcription (32). In the
presence of cycloheximide (10 µg/ml, 1 h), a well-defined inhibitor of protein synthesis, LXA4-induced TF activity
(109 M, 4 h) in ECV304 cells was inhibited by
82 ± 3% (n = 3). LXA4 enhanced
ECV304 cells expression of TF mRNA as assessed by Northern blotting
(Fig. 7). This LXA4-triggered
increase in TF mRNA was also assessed after prior exposure of cells to
pertussis toxin (100 ng/ml, 18 h) As also shown in Fig. 7,
parallel to the TF activity data, LXA4 failed to induce TF
mRNA expression in the presence of pertussis toxin.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LXs are eicosanoids generated via biosynthetic pathways that initially involve the sequential actions of two lipoxygenases, either 5- and 15-lipoxygenases or 5- and 12-lipoxygenases, with arachidonic acid (4). More recently, an additional route of LX formation was demonstrated during neutrophil-endothelial cell interactions involving 5-lipoxygenase and aspirin-acetylated cyclooxygenase-2 (10). These lipid mediators are putative inhibitors of neutrophil trafficking in host defense and inflammation (4). LXs inhibit neutrophil chemotaxis, adhesion to endothelial cells, and transmigration across endothelial cell and epithelial cell monolayers induced by LTs and some other chemoattractants in vitro (11, 22, 28). The potential importance of LXA4 as an eicosanoid with anti-inflammatory actions is further supported by in vivo studies in animal models in which LXA4 and stable analogs of LXA4 inhibit neutrophil recruitment to inflammatory foci (20). In addition to their actions with leukocytes, LXA4 and LXB4 are modulators of bronchial and vascular smooth muscle tone and induce vasodilatation in several vascular beds through an endothelial-dependent mechanism (15).
The formation of LXs within the vascular lumen and vessel wall during
inflammation and after angioplasty places these lipid mediators in a
strategically advantageous site for modulation of the function of a
range of hematogenous and parenchymal cell types.
LXA4 and LXB4, the major bioactive LXs, are
well-defined regulators of endothelial and mesangial cell adhesiveness
for leukocytes, endothelial-dependent vasorelaxation, and chemokine release by epithelial cell lines (reviewed in Refs. 4, 33). In the
present study, we demonstrate that LXA4, at nanomolar
concentrations, induces TF activity by monocytes and HUVEC, cell types
that do not express appreciable TF under basal conditions, and augments TF by ECV304 cells. Indeed, LXA4 induced TF expression by
ECV304 cells to levels equivalent to those induced by TNF- and LPS. TF is an inducible molecule expressed after vessel injury or exposure to cytokines (2, 35). TF initiates blood coagulation
through its interaction with factor VII (17). TF appears
to be an important trigger for thrombosis after acute arterial injury,
and TF-mediated thrombosis may, in turn, be a key stimulus for
subsequent intimal hyperplasia and luminal narrowing (21,
27). Interestingly, TF has recently been reported to promote
recruitment of monocytes in inflammatory renal disease via a
fibrinogen-independent mechanism, thereby expanding the pathogenic
roles of this mediator (14).
The results of our assessment of the structural requirements for LXA4-triggered TF activity are noteworthy for several reasons. First, LXA4 stimulates release of arachidonic acid from several cell types, including leukocytes and endothelial cells, and arachidonic acid enhances TF expression in mononuclear cells (7). Arachidonic acid did not induce TF expression in our study, suggesting that LXA4 regulates ECV304 cell TF expression via a different mechanism. Second, unlike LXA4, LXB4 did not trigger TF expression. LXB4 is the other major LX generated by mammalian cells and shares the ability of LXA4 to influence most other neutrophil and endothelial responses (4, 29). With specific regard to endothelial cells, both LXA4 and LXB4 stimulate prostacyclin generation and inhibit mobilization of P-selectin and endothelial hyperadhesiveness induced by peptidoleukotrienes (28). Third, neither 15(R/S)-methyl-LXA4 nor 16-phenoxy-LXA4 shared the ability of LXA4 to trigger TF expression. The major route for LX metabolism in human leukocytes involves dehydrogenation of alcohols and reduction of double bonds through pathways similar to the dehydrogenation-type systems involved in prostanoid metabolism. LXA4 is metabolized by phorbol myristate acetate-differentiated HL-60 cells and human monocytes to 15-oxo LXA4, 13,14-dihydro-15-oxo-LXA4, and 13,14-dihydro-LXA4 in vitro. 15(R/S)-methyl-LXA4 and 16-phenoxy-LXA4 are analogs of LXA4 that are relatively resistant to degradation in the latter model systems. These compounds share the ability of native LXA4 to inhibit neutrophil-endothelial cell adhesion in vitro and neutrophil trafficking to sites of inflammation induced by LTs in vivo (34, 37). In aggregate, these data establish that the structural requirements for induction of TF expression by LXA4 differ substantially from those described for neutrophil-directed and other parenchymal cell-directed action of LXA4 and suggest involvement of different cell signaling pathways (see below). In addition, the results of these structure-function studies have important implications for drug design, as they suggest that it is possible to discriminate between the well-established anti-inflammatory activities of LXA4 and its potential proinflammatory and prothrombotic effect on TF expression by chemical modification of the native compounds.
Neutrophils, monocytes and epithelial cells express high-affinity (Kd ~1 nM) receptors for LXA4 that have been cloned and characterized and appear to be a member of the superfamily of G protein-coupled chemokine receptors (18, 19, 25). 15(R/S)-methyl-LXA4 and 16-phenoxy-LXA4 compete with LXA4 for binding to these neutrophil receptors and share the ability of LXA4 to inhibit neutrophil chemotaxis and adhesion. In contrast, LXB4 does not compete with LXA4 for binding to this receptor. Human endothelial cells also express high-affinity binding sites for LXA4 (33). There is increasing evidence that nonhematogenous cells, such as endothelial cells and glomerular mesangial cells, express at least two classes of membrane surface receptors for LXA4, one subtype that is specific for LXA4 and another shared by cysteinyl-LTs such as LTD4 (1, 9). In the present study, prior exposure of ECV304 cells to pertussis toxin blocked LXA4-induced TF expression, suggesting that these cells express Gi protein-coupled receptors for LXA4. The failure of 15(R/S)-methyl-LXA4 and 16-phenoxy-LXA4 to mimic the action of LXA4 with regard to TF expression suggests that ECV304 cells express a receptor for LXA4 that is distinct from the myeloid receptor. In further support of this contention, prior exposure of ECV304 cells to 15(R/S)-methyl-LXA4 did not influence the ability of the cells to generate TF on subsequent stimulation by LXA4. Some binding of [3H]LXA4 to endothelial cells is inhibited by the LTD4 receptor antagonist SKF-104353, and both LXA4 and LXB4 antagonize the ability of LTD4 to mobilize endothelial cell P-selectin from Weibel-Palade bodies to the cell surface (28). In our study, SKF-104353 did not antagonize the activity of LXA4 on TF expression, excluding the involvement of this receptor. When viewed in the context of the failure of LXB4 to induce TF expression, the aggregate of these results suggests that LXA4 triggers ECV304 cell TF expression through engagement of novel LXA4 receptors that are distinct from the previously characterized myeloid LXA4 receptor and from the pharmacologically defined SKF-104353-sensitive shared LXA4/LTD4 receptor.
The ability of LXA4 to induce ECV304 cell TF activity was blunted by the PKC inhibitor GF-109203X, but not by genistein, the tyrosine kinase inhibitor. These observations are interesting given that protein kinases C have been implicated in cytokine-triggered induction of TF expression in endothelial cells (38). Furthermore, the failure of genistein to influence LXA4 bioactivity excludes the involvement of tyrosine kinases and again distinguishes this endothelial cell-directed activity of LXA4 from its inhibitory actions with neutrophils that are blunted by genistein (29).
The TF gene is an immediate early gene that is rapidly induced in
various cell types in response to different stimuli. In endothelial
cells, TF gene transcription is activated by LPS, TNF-, and IL-1
(2, 12, 13). The induction of endothelial cell TF gene
expression is controlled by several regulatory elements on the human TF
promoter. The LPS response element is the major cytokine and endotoxin
response element. It includes two activator protein-1 sites and an
NF-
B site that selectively binds cRel/p65 heterodimers
(30). Several observations in the present study suggested
that LXA4 augments ECV304 cell gene expression, at least in
part, by stimulating gene transcription. First, most other mediators
that trigger TF expression do so by stimulating de novo protein
synthesis. Second, the time course of induction of TF activity by
LXA4 in our study was compatible with de novo protein synthesis. Third, both cytokine-triggered and
LXA4-triggered TF activity are modulated by inhibitors of
PKC, suggesting overlap of signal transduction pathways. Fourth,
LXA4 failed to stimulate ECV304 cell TF activity in the
presence of cycloheximide, a well-defined inhibitor of protein synthesis.
Analysis of TF mRNA levels by Northern analysis provided further
evidence that LXA4 triggered TF expression through a
receptor activated cell signaling pathway involving activation of gene transcription. Treatment of ECV304 cells with LXA4 was
associated with an increase in TF mRNA levels. This increase in TF mRNA
expression was inhibited by prior exposure of ECV304 cells to pertussis
toxin, a profile of inhibition that paralleled that noted for
inhibition of LXA4-stimulated TF activity. Interestingly,
induction of TF gene expression appeared to be dissociated from NF-B
activation in this system, thereby distinguishing
LXA4-triggered TF expression from TF expression triggered
by other inflammatory mediators. It should be noted, however, that
there is evidence that LPS and cytokines also stabilize TF mRNA,
thereby suggesting at least two levels of regulation of TF activity
(13). Studies are in progress to investigate the
possibility that LXA4 in addition to inducing TF gene
transcription may also influence TF activity through the latter mechanism.
In summary, the results of the present study demonstrate a novel role
for LXA4 in regulating TF expression and activity. This effect appears to be dose dependent, stereospecific, and mediated through unique G protein-coupled receptors. Complementary studies using
assays of TF bioactivity and mRNA levels suggest that engagement of
LXA4 receptors triggered TF gene expression through a
PKC-dependent and NF-B-independent mechanism. Importantly, studies
of structure-function indicate that it is possible to disassociate
these potentially proinflammatory and prothrombotic effects of
LXA4 from its previously reported capacity to inhibit
neutrophil-endothelial cell interactions and neutrophil recruitment to
sites of inflammation. Finally, these studies establish precedence for
induction of parenchymal cell gene expression by lipoxygenase products.
The identification of other genes regulated by these lipid mediators
should advance our knowledge of the pathophysiology of inflammation,
hypersensitivity, and thrombosis and may suggest novel strategies for
therapeutic intervention.
![]() |
ACKNOWLEDGEMENTS |
---|
We acknowledge Dr. N. A. Petasis and Dr. V. V. Fokin (University of Southern California, Los Angeles, CA) for providing the LXA4 analogs, Dr. N. Mackman (Scripps Research Institute, La Jolla, CA) for providing the pcTF314 containing TF cDNA plasmid, Dr. L. A. J. O' Neill (Trinity College, Dublin, Ireland) for supplying ECV304 cells, and D. Fitzgerald (Royal College of Surgeons, Dublin, Ireland) for supplying HUVECs.
![]() |
FOOTNOTES |
---|
This study was funded by grants from the Irish Heart Foundation (to P. Maderna), the Health Research Board of Ireland (to H. Brady and C. Godson), and the Wellcome Trust (to H. Brady).
Address for reprint requests and other correspondence: H. R. Brady, Centre for Molecular Inflammation and Vascular Research, Dept. of Medicine and Therapeutics, Mater Misericordiae Hospital, Univ. College Dublin, 41 Eccles St., Dublin 7, Ireland (E-mail: hrbrady{at}mater.ie).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 18 June 1999; accepted in final form 6 April 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Badr, KF,
DeBoer DK,
Schwartzberg M,
and
Serhan CN.
Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor.
Proc Natl Acad Sci USA
86:
3438-3442,
1989[Abstract].
2.
Bevilacqua, MP,
Pober JS,
Majeau GR,
Fiers W,
Cotran RS,
and
Gimbrone MA, Jr.
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.
Proc Natl Acad Sci USA
83:
4533-4537,
1986[Abstract].
3.
Bradford, MMA
Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem
72:
248-254,
1976[ISI][Medline].
4.
Brady, HR,
and
Serhan CN.
Lipoxins: putative breaking signals in host defense, inflammation and hypersensitivity.
Curr Opin Nephrol Hypertens
5:
20-27,
1996[Medline].
5.
Bratt, J,
and
Gyllenhammar H.
The role of nitric oxide in lipoxin A4-induced polymorphonuclear neutrophil-dependent cytotoxicity to human vascular endothelium in vitro.
Arthritis Rheum
38:
768-776,
1995[ISI][Medline].
6.
Brezinski, DA,
Nesto RW,
and
Serhan CN.
Angioplasty triggers intracoronary leukotrienes and lipoxin4. Impact of aspirin therapy.
Circulation
86:
56-63,
1992[Abstract].
7.
Cadroy, Y,
Dupouy D,
and
Boneu B.
Arachidonic acid enhances the tissue factor expression of mononuclear cells by the cyclo-oxygenase-1 pathway: beneficial effect of n-3 fatty acids.
J Immunol
160:
6145-6150,
1998
8.
Chomczynski, P,
and
Sacchi N.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:
156-159,
1987[ISI][Medline].
9.
Christie, PE,
Spur BW,
and
Lee TH.
The effects of lipoxin A4 on airway response in asthmatic subjects.
Am Rev Respir Dis
145:
1281-1284,
1992[ISI][Medline].
10.
Claria, J,
and
Serhan CN.
Aspirin triggers novel bioactive eicosanoids by human endothelial cell-leukocyte interactions.
Proc Natl Acad Sci USA
92:
9475-9479,
1995[Abstract].
11.
Colgan, SP,
Serhan CN,
Parkos CA,
Delp-Archer C,
and
Madara JL.
Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial cell monolayers.
J Clin Invest
92:
75-82,
1993[ISI][Medline].
12.
Colucci, M,
Balconi G,
Lorenzet R,
Pietra A,
Locati D,
Donati MB,
and
Semeraro N.
Cultured human endothelial cells generate tissue factor in response to endotoxin.
J Clin Invest
71:
1893-1896,
1983[ISI][Medline].
13.
Crossman, DC,
Carr DP,
Tuddenham EGD,
Pearson JD,
and
McVey JH.
The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester.
J Biol Chem
265:
9782-9787,
1990
14.
Cunningham, MA,
Holdsworth SR,
and
Tipping PG.
Coagulation independent, pro-inflammatory effects of tissue factor/factor VIIa interactions in glomerulonephritis (Abstract).
J Am Soc Nephrol
9:
2421,
1998.
15.
Dahlen, SE,
Veale CA,
Webber SE,
Manon BE,
Nicolaou KC,
and
Serhan CN.
Pharmacodynamics of lipoxin A4 in airway smooth muscle.
Agents Actions
26:
93-95,
1989[ISI][Medline].
16.
Drake, TA,
Hannani K,
Fei H,
Lavi S,
and
Berliner JA.
Minimally oxidized low-density lipoproteins induce tissue factor expression in cultured human endothelial cells.
Am J Pathol
138:
601-607,
1991[Abstract].
17.
Edgington, TS,
Mackman N,
Brand K,
and
Ruf W.
The structural biology of expression and function of tissue factor.
Thromb Haemost
66:
67-79,
1991[ISI][Medline].
18.
Fiore, S,
Maddox JF,
Perez HD,
and
Serhan CN.
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.
J Exp Med
180:
253-260,
1994[Abstract].
19.
Gronert, K,
Gewirtz A,
Madara JL,
and
Serhan CN.
Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon and inhibits tumor necrosis factor-
-induced IL-8 release.
J Exp Med
187:
1285-1294,
1998
20.
Hedqvist, P,
Raud J,
Palmertz J,
Haeggstrom J,
Nicolaou KC,
and
Dahlen SE.
Lipoxin A4 inhibits leukotriene B4-induced inflammation in the hamster cheek pouch.
Acta Physiol Scand
137:
571-581,
1989[ISI][Medline].
21.
Jang, Y,
Guzman LA,
Lincoff AM,
Gottsauner-Wolf M,
Forudi F,
Hart CE,
Courtman DW,
Ezban M,
Ellis SG,
and
Topol EJ.
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.
Circulation
92:
3041-3050,
1995
22.
Lee, TH,
Horton CE,
Kyan-Aungm V,
Haskard D,
Crea AEG,
and
Spur W.
Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by LTB4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.
Clin Sci (Lond)
77:
195-203,
1989[ISI][Medline].
23.
Lopez-Pedrera, C,
Jardi M,
Ingles-Esteve J,
Munoz-Canoves P,
Dorado G,
Velasco F,
and
Felez J.
Characterization of tissue factor expression on the human endothelial cell line ECV304.
Am J Hematol
56:
71-78,
1997[ISI][Medline].
24.
Mackman, N.
Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers.
J Biol Chem
269:
26363-26367,
1994
25.
Maddox, JF,
Hachicha M,
Takano T,
Petasis NA,
Fokin VV,
and
Serhan CN.
Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor.
J Biol Chem
272:
6972-6978,
1997
26.
Morrissey, JH,
Fakhrai H,
and
Edgington TS.
Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade.
Cell
50:
129-135,
1987[ISI][Medline].
27.
Oltrana, L,
Speidel CM,
Recchia D,
and
Abeudschein DR.
Inhibition of tissue factor-mediated thrombosis markedly attenuates stenosis after balloon-induced arterial injury in hyperlipidemic minipigs (Abstract).
Circulation
90:
I-344,
1994.
28.
Papayianni, A,
Rennke H,
Serhan CN,
and
Brady HR.
Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis.
Kidney Int
47:
1295-1302,
1995[ISI][Medline].
29.
Papayianni, A,
Serhan CN,
and
Brady HR.
Lipoxins inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells.
J Immunol
156:
2264-2272,
1996[Abstract].
30.
Parry, GCN,
and
Mackman N.
Transcriptional regulation of tissue factor expression in human endothelial cells.
Arterioscler Thromb Vasc Biol
15:
612-621,
1995
31.
Sambrook, J,
Fritsch EF,
and
Maniatis T
(Editors).
Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
32.
Scarpati, EM,
and
Sadler JE.
Regulation of endothelial cell coagulant properties.
J Biol Chem
264:
20705-20713,
1989
33.
Serhan, CN.
Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?
Prostaglandins
53:
107-137,
1997[Medline].
34.
Serhan, CN,
Maddox JF,
Petasis NA,
Akritopoulou-Zanze I,
Papayianni A,
Brady HR,
Colgan SP,
and
Madara JL.
Design of lipoxin A4 analogs that block transmigration and adhesion of human neutrophils.
Biochemistry
34:
14609-14615,
1995[ISI][Medline].
35.
Speidel, CM,
Eisenberg PR,
Ruf W,
Edgington TS,
and
Abendschein DR.
Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits.
Circulation
92:
3323-3330,
1995
36.
Takahashi, K,
Sawasaki Y,
Hata J,
Mukai K,
and
Goto T.
Spontaneous transformation and immortalization of human endothelial cells.
In Vitro Cell Dev Biol
25:
265-274,
1990.
37.
Takano, T,
Clish CB,
Gronert K,
Petasis N,
and
Serhan CN.
Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.
J Clin Invest
101:
819-826,
1998
38.
Terry, CM,
and
Callahan KS.
Protein kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells.
J Lab Clin Med
127:
81-93,
1996[ISI][Medline].
39.
Tremoli, E,
Eligini S,
Colli S,
Maderna P,
Rise P,
Pazzucconi F,
Marangoni F,
Sirtori CR,
and
Galli C.
n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes.
Arterioscler Thromb
14:
1600-1608,
1994[Abstract].
40.
Tsao, BP,
Fair DS,
Curtiss LK,
and
Edgington TS.
Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/VIIa protease activity.
J Exp Med
159:
1042-1057,
1984[Abstract].